Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor-positive breast cancers

Breast Cancer Research

Volumn 16, Issue 1, 2014, Pages

  Ribas, Ricardo ^a   Ghazoui, Zara ^a,c   Gao, Qiong ^a   Pancholi, Sunil ^a   Rani, Aradhana ^a   Dunbier, Anita ^a,d   Dowsett, Mitch ^a,b   Martin, Lesley Ann ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

^d UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

These data highlight CXCR7 as a potential therapeutic target warranting clinical investigation in endocrine resistant BC

Indexed keywords

ANASTROZOLE; BETA ARRESTIN 1; BETA ARRESTIN 2; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCX733; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR7; CXCL11 CHEMOKINE; FULVESTRANT; KI 67 ANTIGEN; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE INHIBITOR; CHEMOKINE RECEPTOR CXCR; CXCR7 PROTEIN, HUMAN; ESTROGEN RECEPTOR;

ANTIBODY SPECIFICITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER RESISTANCE; CELL COUNT; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; CXCL11 GENE; CXCL12 GENE; CXCR4 GENE; CXCR7 GENE; DOWN REGULATION; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; G1 PHASE CELL CYCLE CHECKPOINT; GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; POSTMENOPAUSE; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; RECURRENCE FREE SURVIVAL; UPREGULATION; BREAST NEOPLASMS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; PHOSPHORYLATION; PROTEIN PROCESSING; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; PHOSPHORYLATION; POSTMENOPAUSE; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, CXCR; RECEPTORS, ESTROGEN; TRANSCRIPTIONAL ACTIVATION;

EID: 84988892895     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/s13058-014-0447-1     Document Type: Article

References (47)

1. Masamura S, Santner SJ, Heitjan DF, Santen RJ: Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab 1995, 80:2918-2925.
2. Coutts AS, Murphy LC: Elevated mitogen-activated protein kinase activity in estrogen-nonresponsive human breast cancer cells. Cancer Res 1998, 58:4071-4074.
3. Santen R, Jeng MH, Wang JP, Song R, Masamura S, McPherson R, Santner S, Yue W, Shim WS: Adaptive hypersensitivity to estradiol: potential mechanism for secondary hormonal responses in breast cancer patients. J Steroid Biochem Mol Biol 2001, 79:115-125.
4. Chan CM, Martin LA, Johnston SR, Ali S, Dowsett M: Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation. J Steroid Biochem Mol Biol 2002, 81:333-341.
5. Martin LA, Farmer I, Johnston SRD, Ali S, Marshall C, Dowsett M: Enhanced estrogen receptor (ER) a, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem 2003, 278:30458-30468.
6. Sabnis GJ, Jelovac D, Long B, Brodie A: The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation. Cancer Res 2005, 65:3903-3910.
7. Masri S, Phung S, Wang X, Wu X, Yuan YC, Wagman L, Chen S: Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor. Cancer Res 2008, 68:4910-4918.
8. Martin LA, Ghazoui Z, Weigel MT, Pancholi S, Dunbier A, Johnston S, Dowsett M: An in vitro model showing adaptation to long-term oestrogen deprivation highlights the clinical potential for targeting kinase pathways in combination with aromatase inhibition. Steroids 2011, 76:772-776.
9. Ellis MJ, Tao Y, Young O, White S, Proia AD, Murray J, Renshaw L, Faratian D, Thomas J, Dowsett M, Krause A, Evans DB, Miller WR, Dixon JM: Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. J Clin Oncol 2006, 24:3019-3025.
10. Duda DG, Kozin SV, Kirkpatrick ND, Xu L, Fukumura D, Jain RK: CXCL12 (SDF1a)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clin Cancer Res 2011, 17:2074-2080.
11. Weigel MT, Ghazoui Z, Dunbier A, Pancholi S, Dowsett M, Martin LA: Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer. Breast Cancer Res 2012, 14:R78.
12. Dunbier AK, Ghazoui Z, Anderson H, Salter J, Nerurkar A, Osin P, A'Hern R, Miller WR, Smith IE, Dowsett M: Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance. Clin Cancer Res 2013, 19:2775-2786.
13. Györffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, Szallasi Z: An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 2010, 123:725-731. http://kmplot.com/analysis/
14. Hattermann K, Held-Feindt J, Lucius R, Müerköster SS, Penfold ME, Schall TJ, Mentlein R: The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects. Cancer Res 2010, 70:3299-3308.
15. Hartmann TN, Grabovsky V, Pasvolsky R, Shulman Z, Buss EC, Spiegel A, Nagler A, Lapidot T, Thelen M, Alon R: A crosstalk between intracellular CXCR7 and CXCR4 involved in rapid CXCL12-triggered integrin activation but not in chemokine-triggered motility of human T lymphocytes and CD34+ cells. J Leukoc Biol 2008, 84:1130-1140.
16. Evans AH, Pancholi S, Farmer I, Thornhill A, Evans DB, Johnston SR, Dowsett M, Martin LA: EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy. Br J Cancer 2010, 102:1235-1243.
17. Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, McShane L, Paik S, Penault-Llorca F, Prudkin L, Regan M, Salter J, Sotiriou C, Smith IE, Viale G, Zujewski JA, Hayes DF: Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst 2011, 103:1656-1664.
18. Levoye A, Balabanian K, Baleux F, Bachelerie F, Lagane B: CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood 2009, 113:6085-6093.
19. Hawkins OE, Richmond A: The dynamic yin-yang interaction of CXCR4 and CXCR7 in breast cancer metastasis. Breast Cancer Res 2012, 14:103.
20. Berahovich RD, Penfold ME, Schall TJ: Nonspecific CXCR7 antibodies. Immunol Lett 2010, 133:112-114.
21. Rajagopal S, Kim J, Ahn S, Craig S, Lam CM, Gerard NP, Gerard C, Lefkowitz RJ: B-arrestin-but not G protein-mediated signaling by the "decoy" receptor CXCR7. Proc Natl Acad Sci U S A 2010, 107:628-632.
22. + T cell survival and autoimmunity by β-arrestin 1. Nat Immunol 2007, 8:817-824.
23. Nair BC, Nair SS, Chakravarty D, Challa R, Manavathi B, Yew PR, Kumar R, Tekmal RR, Vadlamudi RK: Cyclin-dependent kinase-mediated phosphorylation plays a critical role in the oncogenic functions of PELP1. Cancer Res 2010, 70:7166-7175.
24. Burns JM, Summers BC, Wang Y, Melikian A, Berahovich R, Miao Z, Penfold ME, Sunshine MJ, Littman DR, Kuo CJ, Wei K, McMaster BE, Wright K, Howard MC, Schall TJ: A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 2006, 203:2201-2213.
25. Andre F, Cabioglu N, Assi H, Sabourin JC, Delaloge S, Sahin A, Broglio K, Spano JP, Combadiere C, Bucana C, Soria JC, Cristofanilli M: Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. Ann Oncol 2006, 17:945-951.
26. Su YC, Wu MT, Huang CJ, Hou MF, Yang SF, Chai CY: Expression of CXCR4 is associated with axillary lymph node status in patients with early breast cancer. Breast 2006, 15:533-539.
27. Lapteva N, Yang AG, Sanders DE, Strube RW, Chen SY: CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo. Cancer Gene Ther 2005, 12:84-89.
28. Liang Z, Wu H, Reddy S, Zhu A, Wang S, Blevins D, Yoon Y, Zhang Y, Shim H: Blockade of invasion and metastasis of breast cancer cells via targeting CXCR4 with an artificial microRNA. Biochem Biophys Res Commun 2007, 363:542-546.
29. Boudot A, Kerdivel G, Habauzit D, Eeckhoute J, Le Dily F, Flouriot G, Samson M, Pakdel F: Differential estrogen-regulation of CXCL12 chemokine receptors, CXCR4 and CXCR7, contributes to the growth effect of estrogens in breast cancer cells. PLoS One 2011, 6:e20898.
30. Luker KE, Lewin SA, Mihalko LA, Schmidt BT, Winkler JS, Coggins NL, Thomas DG, Luker GD: Scavenging of CXCL12 by CXCR7 promotes tumor growth and metastasis of CXCR4-positive breast cancer cells. Oncogene 2012, 31:4750-4758.
31. Moore CA, Milano SK, Benovic JL: Regulation of receptor trafficking by GRKs and arrestins. Annu Rev Physiol 2007, 69:451-482.
32. DeWire SM, Ahn S, Lefkowitz RJ: Shenoy SK: β-arrestins and cell signaling. Annu Rev Physiol 2007, 69:483-510.
33. Kang J, Shi Y, Xiang B, Qu B, Su W, Zhu M, Zhang M, Bao G, Wang F, Zhang X, Yang R, Fan F, Chen X, Pei G, Ma L: A nuclear function of β-arrestin 1 in GPCR signaling: regulation of histone acetylation and gene transcription. Cell 2005, 123:833-847. A published erratum appears in Cell 2006, 124:645.
34. Frederick TJ, Miller SD: Arresting autoimmunity by blocking β-arrestin 1. Nat Immunol 2007, 8:791-792.
35. Shankar H, Michal A, Kern RC, Kang DS, Gurevich VV, Benovic JL: Non-visual arrestins are constitutively associated with the centrosome and regulate centrosome function. J Biol Chem 2010, 285:8316-8329.
36. 2-adrenoreceptors and β-arrestin-1. Nature 2011, 477:349-353.
37. Lakshmikanthan V, Zou L, Kim JI, Michal A, Nie Z, Messias NC, Benovic JL, Daaka Y: Identification of βArrestin2 as a corepressor of androgen receptor signaling in prostate cancer. Proc Natl Acad Sci U S A 2009, 106:9379-9384.
38. Singh RK, Lokeshwar BL: The IL-8-regulated chemokine receptor CXCR7 stimulates EGFR signaling to promote prostate cancer growth. Cancer Res 2011, 71:3268-3277.
39. Martin LA, Pancholi S, Chan CM, Farmer I, Kimberley C, Dowsett M, Johnston SR: The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling. Endocr Relat Cancer 2005, 12:1017-1036.
40. Zheng H, Dai T, Zhou B, Zhu J, Huang H, Wang M, Fu G: SDF-1a/CXCR4 decreases endothelial progenitor cells apoptosis under serum deprivation by PI3K/Akt/eNOS pathway. Atherosclerosis 2008, 201:36-42.
41. Ghayad SE, Vendrell JA, Ben Larbi S, Dumontet C, Bieche I, Cohen PA: Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Int J Cancer 2010, 126:545-562.
42. Sauvé K, Lepage J, Sanchez M, Heveker N, Tremblay A: Positive feedback activation of estrogen receptors by the CXCL12-CXCR4 pathway. Cancer Res 2009, 69:5793-5800.
43. Rhodes LV, Short SP, Neel NF, Salvo VA, Zhu Y, Elliott S, Wei Y, Yu D, Sun M, Muir SE, Fonseca JP, Bratton MR, Segar C, Tilghman SL, Sobolik-Delmaire T, Horton LW, Zaja-Milatovic S, Collins-Burow BM, Wadsworth S, Beckman BS, Wood CE, Fuqua SA, Nephew KP, Dent P, Worthylake RA, Curiel TJ, Hung MC, Richmond A, Burow ME: Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Cancer Res 2011, 71:603-613. A published erratum appears in Cancer Res 2011, 71:3432.
44. Ali S, Coombes RC: Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2002, 2:101-112.
45. Musgrove EA, Sutherland RL: Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009, 9:631-643.
46. Xu J, Wu RC, O'Malley BW: Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family. Nat Rev Cancer 2009, 9:615-630.
47. Gururaj AE, Rayala SK, Vadlamudi RK, Kumar R: Novel mechanisms of resistance to endocrine therapy: genomic and nongenomic considerations. Clin Cancer Res 2006, 12:1001s-1007s.